Metastatic Prostate Carcinoma
Information
- Disease name
- Metastatic Prostate Carcinoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02807805 | Active, not recruiting | Phase 2 | Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | October 2016 | July 2024 |
| NCT04592237 | Active, not recruiting | Phase 2 | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | December 29, 2020 | December 31, 2025 |
| NCT02881242 | Active, not recruiting | Phase 2 | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | January 30, 2018 | January 31, 2025 |
| NCT02893917 | Active, not recruiting | Phase 2 | Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer | August 11, 2017 | June 7, 2025 |
| NCT04514484 | Active, not recruiting | Phase 1 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | November 22, 2021 | November 2, 2025 |
| NCT01953640 | Active, not recruiting | Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy | May 28, 2013 | June 30, 2024 | |
| NCT04447703 | Active, not recruiting | N/A | Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study | August 27, 2020 | September 2029 |
| NCT04267887 | Active, not recruiting | Phase 2 | Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer | May 11, 2020 | January 1, 2030 |
| NCT03012321 | Active, not recruiting | Phase 2 | Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | January 12, 2017 | January 16, 2027 |
| NCT02522715 | Active, not recruiting | Phase 1/Phase 2 | Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | October 13, 2015 | July 1, 2024 |
| NCT03805594 | Active, not recruiting | Phase 1 | 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | May 10, 2019 | April 30, 2025 |
| NCT03217747 | Active, not recruiting | Phase 1/Phase 2 | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | August 2, 2017 | September 30, 2024 |
| NCT03218826 | Active, not recruiting | Phase 1 | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | September 24, 2018 | September 22, 2024 |
| NCT03873805 | Active, not recruiting | Phase 1 | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer | August 20, 2019 | December 31, 2024 |
| NCT05241860 | Active, not recruiting | Phase 2 | Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) | November 21, 2022 | September 1, 2033 |
| NCT03503097 | Active, not recruiting | Genetic Testing for Men With Metastatic Prostate Cancer | August 21, 2017 | August 21, 2024 | |
| NCT03517969 | Active, not recruiting | Phase 2 | M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | May 29, 2019 | December 31, 2024 |
| NCT03821792 | Active, not recruiting | Phase 2 | Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | July 22, 2019 | October 1, 2024 |
| NCT04716725 | Active, not recruiting | Phase 2 | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer | September 28, 2021 | April 30, 2025 |
| NCT02703623 | Active, not recruiting | Phase 2 | Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | May 18, 2016 | March 31, 2026 |
| NCT03707184 | Completed | Phase 2 | Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone | October 2, 2018 | February 3, 2022 |
| NCT01505868 | Completed | Phase 1/Phase 2 | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | July 11, 2012 | December 9, 2019 |
| NCT01522820 | Completed | Phase 1 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | March 2012 | July 2016 |
| NCT01881867 | Completed | Phase 2 | CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer | September 10, 2013 | January 2, 2018 |
| NCT02159950 | Completed | Phase 2 | Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | January 2015 | |
| NCT05547386 | Completed | Phase 3 | 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer | May 9, 2022 | December 31, 2023 |
| NCT02458716 | Completed | Phase 1 | Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer | March 6, 2015 | January 14, 2020 |
| NCT02499835 | Completed | Phase 1/Phase 2 | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer | July 1, 2015 | July 27, 2023 |
| NCT00942331 | Completed | Phase 3 | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | July 15, 2009 | June 15, 2021 |
| NCT02532114 | Completed | Phase 1 | Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer | December 31, 2015 | November 30, 2017 |
| NCT02555189 | Completed | Phase 1/Phase 2 | Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression | December 1, 2015 | September 1, 2023 |
| NCT02598895 | Completed | Phase 2 | Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway | January 26, 2016 | September 14, 2021 |
| NCT01503229 | Completed | Phase 2 | Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | December 2012 | March 12, 2020 |
| NCT04050215 | Completed | Phase 2 | 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer | April 2, 2018 | September 27, 2021 |
| NCT03123978 | Completed | Phase 1 | Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer | January 9, 2017 | April 19, 2022 |
| NCT03448458 | Completed | Phase 2 | Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer | February 22, 2018 | February 6, 2023 |
| NCT03456804 | Completed | Phase 2 | ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | March 8, 2018 | May 9, 2023 |
| NCT03751436 | Completed | Phase 1 | Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer | August 2, 2019 | August 11, 2023 |
| NCT06422455 | Not yet recruiting | N/A | Access to Genetic Testing in Underserved Patients With Cancer | July 1, 2024 | July 1, 2027 |
| NCT05487846 | Not yet recruiting | N/A | Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation | November 14, 2024 | May 31, 2026 |
| NCT05398302 | Recruiting | Phase 1 | Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy | April 26, 2024 | December 31, 2026 |
| NCT02935205 | Recruiting | Phase 1/Phase 2 | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer | January 17, 2017 | December 2024 |
| NCT03987217 | Recruiting | Early Phase 1 | Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients | June 17, 2019 | June 7, 2026 |
| NCT04071236 | Recruiting | Phase 1/Phase 2 | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy | October 14, 2020 | January 31, 2025 |
| NCT04159896 | Recruiting | Phase 2 | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | November 13, 2019 | March 1, 2022 |
| NCT04314401 | Recruiting | National Cancer Institute "Cancer Moonshot Biobank" | November 11, 2020 | September 16, 2025 | |
| NCT04388852 | Recruiting | Phase 1 | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | August 20, 2020 | December 31, 2026 |
| NCT04423211 | Recruiting | Phase 3 | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | October 8, 2020 | December 31, 2032 |
| NCT04489719 | Recruiting | Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer | April 16, 2021 | August 1, 2028 | |
| NCT04550494 | Recruiting | Phase 2 | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | April 26, 2021 | December 1, 2024 |
| NCT04693377 | Recruiting | N/A | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial | March 16, 2021 | April 1, 2027 |
| NCT04927663 | Recruiting | Phase 1 | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression | August 10, 2021 | October 31, 2025 |
| NCT05627219 | Recruiting | Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network | June 3, 2024 | April 29, 2026 | |
| NCT05805371 | Recruiting | Phase 1 | PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer | June 12, 2024 | July 1, 2028 |
| NCT05869682 | Recruiting | Phase 2 | Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy | June 15, 2024 | December 1, 2027 |
| NCT06040125 | Recruiting | N/A | Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial | January 1, 2024 | February 28, 2027 |
| NCT06244004 | Recruiting | Phase 2 | FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial | February 18, 2024 | February 18, 2028 |
| NCT06305598 | Recruiting | Phase 1 | Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer | June 1, 2024 | April 1, 2027 |
| NCT02491411 | Terminated | N/A | Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel | September 2015 | March 2018 |
| NCT03011749 | Terminated | N/A | Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients | January 2017 | February 2018 |
| NCT04279561 | Terminated | Phase 1 | Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer | April 16, 2020 | September 15, 2022 |
| NCT04928820 | Terminated | Phase 2 | 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy | June 16, 2021 | October 18, 2022 |
| NCT02565901 | Terminated | Phase 1/Phase 2 | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | February 29, 2016 | June 16, 2020 |
| NCT02985021 | Terminated | Phase 2 | Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies | November 2016 | April 2021 |
| NCT02516670 | Terminated | Phase 2 | Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer | June 20, 2016 | October 14, 2021 |
| NCT02853097 | Terminated | Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients | June 14, 2016 | September 27, 2020 | |
| NCT03649841 | Terminated | Phase 2 | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer | June 29, 2020 | February 1, 2023 |
| NCT02429804 | Terminated | Phase 1 | NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer | April 2015 | May 15, 2017 |
| NCT03999515 | Terminated | Phase 2 | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer | April 27, 2020 | June 6, 2021 |
| NCT04134208 | Terminated | Phase 4 | An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer | September 19, 2019 | June 28, 2022 |
| NCT02370355 | Terminated | Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer | December 23, 2014 | June 8, 2016 | |
| NCT03016741 | Unknown status | Phase 4 | Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer | March 31, 2017 | August 2023 |
| NCT02691975 | Unknown status | Phase 1/Phase 2 | A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients | April 12, 2016 | June 1, 2021 |
| NCT02935023 | Unknown status | Phase 2 | Carbon Ion Radiotherapy in Treating Patients Undergoing Systemic Therapy for Oligo-metastatic Prostate Cancer | September 2016 | September 2019 |
| NCT04585932 | Withdrawn | Phase 2 | Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study | November 24, 2020 | January 8, 2021 |
| NCT03596710 | Withdrawn | N/A | Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy | June 14, 2018 | June 14, 2022 |
| NCT05034562 | Withdrawn | Phase 2 | Gallium-68 PSMA-11 PET in Participants With Prostate Cancer | September 26, 2022 | September 26, 2022 |